Apr 6, 2021 Nat Commun
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses
Ogbe, A., Kronsteiner, B., Skelly, D.T., Pace, M., Brown, A., Adland, E., Adair, K., Akhter, H.D., Ali, M., Ali, S.E., Angyal, A., Ansari, M.A., Arancibia-Cárcamo, C.V., Brown, H., Chinnakannan, S., Conlon, C., de Lara, C., de Silva, T., Dold, C., Dong, T., Donnison, T., Eyre, D., Flaxman, A., Fletcher, H., Gardner, J., Grist, J.T., Hackstein, C.P., Jaruthamsophon, K., Jeffery, K., Lambe, T., Lee, L., Li, W., Lim, N., Matthews, P.C., Mentzer, A.J., Moore, S.C., Naisbitt, D.J., Ogese, M., Ogg, G., Openshaw, P., Pirmohamed, M., Pollard, A.J., Ramamurthy, N., Rongkard, P., Rowland-Jones, S., Sampson, O., Screaton, G., Sette, A., Stafford, L., Thompson, C., Thomson, P.J., Thwaites, R., Vieira, V., Weiskopf, D., Zacharopoulou, P.; Oxford Immunology Network Covid-19 Response T Cell Consortium; Oxford Protective T Cell Immunology for COVID-19 (OPTIC) Clinical Team, Turtle, L., Klenerman, P., Goulder, P., Frater, J., Barnes, E., and Dunachie, S.